import type { Metadata } from "next";
import Image from "next/image";
import "./uterine-lms.css";

export const metadata: Metadata = {
  title: "Uterine Leiomyosarcoma | NLMSF",
  description:
    "Clinically relevant research, reviews, clinical trials, and education focused on uterine leiomyosarcoma.",
};

const verbatimArchiveHtml = `
<div class="elementor-widget-wrap">
  <div class="elementor-element elementor-widget elementor-widget-text-editor">
    <div class="elementor-widget-container">
      <div class="elementor-text-editor elementor-clearfix">
        <div>
          <div dir="ltr" data-setdir="false">
            <div>
              <div dir="ltr" data-setdir="false">
                <h1><span style="font-size: medium;">Uterine smooth muscle tumors of uncertain malignant potential: a 13-year retrospective study (7 November 2024)</span></h1>
              </div>
              <div dir="ltr" data-setdir="false">
                <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816</a>
              </div>
            </div>
            <div>&nbsp;</div>
            <div><strong><span style="font-size: large;">Recent Research Articles Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma</span></strong></div>
            <div>Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD, Movva S, Maki RG, Antonescu CR. Purpose: Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous tumors. Despite genomic studies, current LMS risk stratification is not informed by molecular alterations. We propose a clinically applicable genomic risk stratification model. Clinical Cancer Research, 2024 Mar 15. Online ahead of print. PMID: 38488807. DOI: 10.1158/1078-0432.CCR-24-0148</div>
            <div>
              <a href="https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext" target="_blank" rel="noopener">https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext</a>
            </div>
            <div>&nbsp;</div>
            <div><strong><span style="font-size: large;">The Future of Targeted Therapy for Leiomyosarcoma New from MD Anderson:</span></strong></div>
            <div>Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddid E. Abstract: Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology. Cancers, 2024 Feb. 26, DOI: 10.3390/cancers16050938.</div>
            <p><a href="https://www.mdpi.com/2072-6694/16/5/938" target="_blank" rel="noopener">https://www.mdpi.com/2072-6694/16/5/938</a></p>
          </div>
          <div>&nbsp;</div>
          <h3>About Aromatase Inhibitors:</h3>
          <p><strong>Q:</strong> Studies on Letrozole - debate on whether it is best for Stage 1,2 uLMS instead of advanced stages 3, 4:</p>
          <p><strong>A:</strong> Letrozole has been best studied (though small studies) in the metastatic setting. Here is a link to a publication from the DFCI group: <a href="https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476" target="_blank" rel="noopener">https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476</a> It is really not clear how much benefit these drugs have, but anecdotally patients can benefit.</p>
          <ul>
            <li>Matt Hemming, MD, Dana Farber Cancer Institute / LMS International Research Roundtable Workgroup Leader for LMS cell lines / PDX model</li>
          </ul>
        </div>
      </div>
    </div>
  </div>
  <div class="elementor-element elementor-widget elementor-widget-text-editor">
    <div class="elementor-widget-container">
      <div class="elementor-text-editor elementor-clearfix">
        <ul>
          <li>Suzanne George, Dana Farber Cancer Institute / LMS International Research Roundtable Member</li>
        </ul>
        <h4>UTERINE LMS and Temolizomide / Olaparib treatment strategy</h4>
        <h4><strong>Dr. Matthew Ingham and Dr. Sam Bose present on Advanced uterine LMS - the Clinical Science Symposium at ASCO: </strong><a href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma" target="_blank" rel="noopener"><strong>https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma</strong></a></h4>
        <p><strong>Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma</strong> - <a href="https://pubmed.ncbi.nlm.nih.gov/35660331/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/35660331/</a></p>
        <p><strong>Novel Therapeutic Strategies targeting UCP2 in uLMS:</strong><br>
        <a href="https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub</a></p>
        <p><strong>Overlap of Suspicious and Non-suspicious features in the Ultrasound Evaluation of Leiomyosarcoma - a Single-Center Experience</strong><br>
        <a href="https://www.mdpi.com/2075-4418/13/3/543" target="_blank" rel="noopener">https://www.mdpi.com/2075-4418/13/3/543</a></p>
        <p><a style="color: #99cc00;" href="https://leiomyosarcoma.info/wp-content/uploads/2022/02/Uterine-LMS-Staging-Chart-and-comprehensive-study.docx.pdf">Uterine LMS Staging Chart and comprehensive study</a></p>
        <h3>Uterine LMS Research Rapid</h3>
        <ul>
          <li>
            <blockquote>
              <div>Important Video presentation on Uterine LMS research progress updates provided by Dr. Matthew Ingham, Columbia University Medical Center, on uterine sarcomas at the American Society of Clinical Oncology (ASCO)</div>
              <div><a href="https://www.vumedi.com/video/asco-2022-novel-therapeutics-in-the-treatment-of-uterine-sarcoma/?token=7f15b18e-df52-41f3-8c3b-e2ef7ff73686" target="_blank" rel="nofollow noopener noreferrer">ASCO 2022: Novel Therapeutics in the Treatment of Uterine Sarcoma</a> - link: <a href="https://bit.ly/3qqNM6d" target="_blank" rel="noopener">https://bit.ly/3qqNM6d</a></div>
            </blockquote>
          </li>
          <li>
            <blockquote>
              <div>Dr. Ingham is an esteemed member of the NLMSF-SPAGN International LMS Research Roundtable and on the Executive Committee of the NLMSF.</div>
              <div>His presentation to the NLMSF Patient - Caregiver Advocacy Roundtable is here: <a href="https://youtu.be/mY2q7q5VOlA" target="_blank" rel="nofollow noopener noreferrer">https://youtu.be/mY2q7q5VOlA</a></div>
              <div><u>Clinical Trial on Uterine LMS (last updated Aug 24, 2022):</u></div>
              <div>A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma - PI: Mathew Ingham, MD - <a href="https://clinicaltrials.gov/ct2/show/NCT03880019" target="_blank" rel="nofollow noopener noreferrer">NCT03880019</a></div>
              <div>Additionally, Dr. Gary Schwartz presented to the NLMSF Patient-Caregiver Advocacy Roundtable:</div>
              <div><strong>Dr. Gary Schwartz discussed the large clinical trial going into Phase III for uterine LMS clinical trial update:</strong> <a href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma" target="_blank" rel="nofollow noopener noreferrer">OncLive article</a></div>
              <div>Recorded presentation: <a href="https://youtu.be/62gyn3nt6Z8" target="_blank" rel="nofollow noopener noreferrer">https://youtu.be/62gyn3nt6Z8</a></div>
            </blockquote>
          </li>
          <li><a href="https://www.mdpi.com/1422-0067/23/17/9728/htm" target="_blank" rel="noopener">Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review</a></li>
          <li><a href="https://www.prnewswire.com/news-releases/preliminary-results-presented-at-asco-demonstrated-promising-clinical-efficacy-with-unesbulin-in-leiomyosarcoma-study-301560763.html" target="_blank" rel="noopener">New and promising drug - Unesbulin</a></li>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/35726279/" target="_blank" rel="noopener">Long-Term Efficacy and Safety of Anlotinib for Advanced Sarcomas</a></li>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/35715148/" target="_blank" rel="noopener">Leiomyosarcoma: Current Clinical Management and Future Horizon</a></li>
        </ul>
        <h3>Uterine LMS Treatment - from the American Cancer Society</h3>
        <h4>Leiomyosarcoma and undifferentiated sarcoma</h4>
        <p><strong>Stages I and II:</strong> Standard surgery is hysterectomy with BSO; lymph node evaluation as indicated. Adjuvant radiation may reduce local recurrence; chemo is considered in higher-risk cases.</p>
        <p><strong>Stage III:</strong> Debulking/definitive surgery followed by radiation +/- chemo depending on risk of recurrence.</p>
        <p><strong>Stage IV:</strong> IVA may be operable; otherwise radiation/chemo or both. IVB managed with systemic therapy; targeted therapy when appropriate.</p>
        <p>See ACS for details: Surgery, Radiation therapy, Chemotherapy, Targeted therapy.</p>
      </div>
    </div>
  </div>
</div>
`;

export default function UterineLmsPage() {
  return (
    <main className="uterine-lms-page">
      <section className="wp-hero">
        <div className="wp-hero-inner">
          <span className="wp-hero-badge">NLMSF Knowledge Hub</span>
          <h1 className="wp-hero-title">Uterine Leiomyosarcoma (uLMS)</h1>
          <p className="wp-hero-sub">
            Clinically relevant research, reviews, clinical trials, and education focused on
            uterine leiomyosarcoma.
          </p>
        </div>
      </section>

      <section className="uterine-layout">
        <aside className="wp-sidebar">
          <nav className="wp-nav" aria-label="On this page">
            <a className="wp-nav-link" href="#featured-publication">
              Featured Publication
            </a>
            <a className="wp-nav-link" href="#expert-video">
              Expert Video
            </a>
            <a className="wp-nav-link" href="#recent-literature">
              Recent Literature
            </a>
            <a className="wp-nav-link" href="#genomic-risk">
              Genomic Risk Stratification
            </a>
            <a className="wp-nav-link" href="#targeted-therapy">
              Targeted Therapy Review
            </a>
            <a className="wp-nav-link" href="#hormone-therapy">
              Hormone Therapy (AIs)
            </a>
            <a className="wp-nav-link" href="#research-links">
              Research & Clinical Trials
            </a>
            <a className="wp-nav-link" href="#full-research-archive">
              Full Research Archive
            </a>
          </nav>
          <Image
            src="https://media.nlmsf.org/wp-content/uploads/2025/11/research-uterine.png"
            alt="Research uterine"
            className="wp-sidebar-image"
            width={320}
            height={240}
          />
          <div className="wp-sidebar-cta">
            <h4>Stay Informed</h4>
            <p>Get monthly updates on uterine LMS research and resources.</p>
            <a className="wp-cta-btn" href="https://nlmsf.org/subscribe/" target="_blank" rel="noopener noreferrer">
              Subscribe
            </a>
          </div>
        </aside>

        <div className="content-container">
          <section id="featured-publication" className="section">
            <h2 className="section-title gradient-text">Featured Publication</h2>
            <div className="card pub-card">
              <div className="pub-media">
                <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener noreferrer">
                  <Image
                    src="https://leiomyosarcoma.info/wp-content/uploads/2021/03/Cancers.png"
                    alt="Featured Research"
                    width={240}
                    height={180}
                  />
                </a>
              </div>
              <div className="pub-body">
                <h3 className="pub-title">
                  <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener noreferrer">
                    Uterine SM Tumors of Uncertain Malignant Potential - 13-year retrospective study (2024)
                  </a>
                </h3>
                <p className="muted">
                  Comprehensive retrospective study informing diagnosis and management for uterine
                  smooth muscle tumors of uncertain malignant potential.
                </p>
              </div>
            </div>
          </section>

          <section id="expert-video" className="section">
            <h2 className="section-title gradient-text">Expert Video: Sarcoma Care Insights</h2>
            <div className="card">
              <h3 className="card-title">Uterine Sarcoma Care - Key Considerations</h3>
              <div className="video-wrapper">
                <iframe
                  src="https://www.youtube.com/embed/KzPj_xrz334"
                  title="Uterine Sarcoma Care"
                  allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share"
                  allowFullScreen
                />
              </div>
              <p className="muted">
                Multidisciplinary sarcoma programs bring together surgical, medical, and radiation
                oncology expertise, with access to advanced imaging and clinical trials. For an
                overview of comprehensive sarcoma services - including evaluation, treatment
                planning, and second opinions - see the{" "}
                <a className="resource-link" href="https://www.uclahealth.org/cancer/cancer-services/sarcoma" target="_blank" rel="noopener noreferrer">
                  UCLA Health Sarcoma Center
                </a>
                .
              </p>
            </div>
          </section>

          <section id="recent-literature" className="section">
            <h2 className="section-title gradient-text">Recent Literature: IJGC Review (2025)</h2>
            <div className="literature-card">
              <h3 className="literature-title">Uterine Leiomyosarcoma - International Panel Review</h3>
              <p className="literature-meta">International Journal of Gynecological Cancer - September 2025 - Review</p>
              <ul className="lit-bullets">
                <li><strong>Biology</strong>: Multifactorial pathogenesis with complex cytogenetic/molecular alterations (e.g., TP53, RB1; chromothripsis patterns).</li>
                <li><strong>Diagnosis</strong>: Preoperative distinction from leiomyoma remains difficult; MRI/CT assist but no single definitive test. Avoid morcellation when malignancy is suspected.</li>
                <li><strong>Primary treatment</strong>: Stage I - en bloc total hysterectomy +/- BSO; routine lymphadenectomy not indicated without bulky nodes. Centralized, multidisciplinary care is emphasized.</li>
                <li><strong>Stage II-IV/recurrent</strong>: Aim for complete resection when feasible; adjuvant chemo/RT evidence is mixed. Systemic options are doxorubicin-based; consider RT and multimodal strategies.</li>
                <li><strong>Follow-up</strong>: Regular clinical and imaging surveillance due to high early recurrence risk; patterns often distant (lung/liver).</li>
                <li><strong>Guidelines & variability</strong>: ESGO/EURACAN/GCIG recommendations summarized; notable international practice differences persist.</li>
              </ul>
              <a className="lit-link" href="https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)01112-0/fulltext" target="_blank" rel="noopener noreferrer">
                Read the full IJGC 2025 review
              </a>
            </div>
          </section>

          <section id="genomic-risk" className="section">
            <h2 className="section-title gradient-text">Genomic Risk Stratification in uLMS</h2>
            <div className="card">
              <h3 className="card-title">Developing Novel Genomic Risk Stratification Models</h3>
              <p>
                Dermawan JK et al. propose a clinically applicable genomic risk model for LMS,
                addressing heterogeneity and current gaps in risk tools.
              </p>
              <ul className="resource-list">
                <li>
                  <a className="resource-link" href="https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext" target="_blank" rel="noopener noreferrer">
                    Clinical Cancer Research (2024) - Abstract
                  </a>
                </li>
                <li>
                  <a className="resource-link" href="https://doi.org/10.1158/1078-0432.CCR-24-0148" target="_blank" rel="noopener noreferrer">
                    DOI: 10.1158/1078-0432.CCR-24-0148
                  </a>
                </li>
              </ul>
            </div>
            <div className="card">
              <h3 className="card-title">Transcriptome profiling: leiomyoma-like program indicates better survival</h3>
              <p>
                Multi-cohort transcriptomic profiling identifies a subset of uterine LMS with a
                leiomyoma-like expression pattern associated with more favorable outcomes.
              </p>
              <ul className="resource-list">
                <li>
                  <a className="resource-link" href="https://www.nature.com/articles/s44276-025-00190-x" target="_blank" rel="noopener noreferrer">
                    Nature (2025) - Article
                  </a>
                </li>
              </ul>
            </div>
          </section>

          <section id="targeted-therapy" className="section">
            <h2 className="section-title gradient-text">Targeted Therapy - MD Anderson Review</h2>
            <div className="card">
              <h3 className="card-title">The Future of Targeted Therapy for Leiomyosarcoma</h3>
              <p>
                Review of DNA damage response, macrophage-rich microenvironment, PI3K/mTOR,
                epigenetic regulators, and telomere biology in LMS.
              </p>
              <ul className="resource-list">
                <li>
                  <a className="resource-link" href="https://www.mdpi.com/2072-6694/16/5/938" target="_blank" rel="noopener noreferrer">
                    Cancers (2024): 10.3390/cancers16050938
                  </a>
                </li>
              </ul>
            </div>
          </section>

          <section id="hormone-therapy" className="section">
            <h2 className="section-title gradient-text">Hormone Therapy: Aromatase Inhibitors</h2>
            <div className="card">
              <h3 className="card-title">Letrozole and AI use in uLMS</h3>
              <p>
                <strong>Q:</strong> Studies on Letrozole - suitability for stage I/II vs advanced
                (III/IV)?
                <br />
                <strong>A:</strong> Best studied in metastatic setting; benefit variable; some
                patients may benefit anecdotally.
              </p>
              <ul className="resource-list">
                <li>
                  <a className="resource-link" href="https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476" target="_blank" rel="noopener noreferrer">
                    DFCI publication (Cancer)
                  </a>
                </li>
                <li>
                  <a className="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/19932916/" target="_blank" rel="noopener noreferrer">
                    Treatment of advanced uLMS with aromatase inhibitors
                  </a>
                </li>
                <li>
                  <a className="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/24222211/" target="_blank" rel="noopener noreferrer">
                    Phase II Letrozole in ER/PR+ uLMS
                  </a>
                </li>
                <li>
                  <a className="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/25018868/" target="_blank" rel="noopener noreferrer">
                    Hormone-positive uLMS with AIs
                  </a>
                </li>
              </ul>
            </div>
          </section>

          <section id="research-links" className="section">
            <h2 className="section-title gradient-text">Research & Clinical Trials</h2>
            <ul className="resource-list">
              <li>
                <a className="resource-link" href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma" target="_blank" rel="noopener noreferrer">
                  Temozolomide + Olaparib shows encouraging efficacy in uLMS
                </a>
              </li>
              <li>
                <a className="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/35660331/" target="_blank" rel="noopener noreferrer">
                  Adjuvant therapy utilization outcomes - Stage II/III uLMS
                </a>
              </li>
              <li>
                <a className="resource-link" href="https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub" target="_blank" rel="noopener noreferrer">
                  Targeting UCP2 in uLMS
                </a>
              </li>
              <li>
                <a className="resource-link" href="https://www.mdpi.com/2075-4418/13/3/543" target="_blank" rel="noopener noreferrer">
                  Overlap of suspicious features on ultrasound - single center
                </a>
              </li>
              <li>
                <a className="resource-link" href="https://leiomyosarcoma.info/wp-content/uploads/2022/02/Uterine-LMS-Staging-Chart-and-comprehensive-study.docx.pdf" target="_blank" rel="noopener noreferrer">
                  Uterine LMS Staging Chart - comprehensive study
                </a>
              </li>
            </ul>
          </section>

          <section id="full-research-archive" className="section">
            <h2 className="section-title gradient-text">Full Research Archive (Verbatim)</h2>
            <p className="muted">
              Imported as provided to ensure every original item appears. Collapsed by default for
              readability.
            </p>
            <details className="raw-archive">
              <summary>View full archive</summary>
              <div
                className="raw-archive-inner"
                dangerouslySetInnerHTML={{ __html: verbatimArchiveHtml }}
              />
            </details>
          </section>
        </div>
      </section>
    </main>
  );
}
